Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc (NYSE: BAX) is a global healthcare leader specializing in life-saving renal care, advanced medical devices, and hospital solutions. This page provides investors and healthcare professionals with timely updates on the company’s operational developments, regulatory milestones, and strategic initiatives.
Access authoritative information about Baxter’s latest financial results, product innovations, and partnerships. Our curated news collection simplifies tracking of critical updates across key areas including dialysis technologies, infusion systems, and biosurgery products.
Discover official announcements regarding:
• Quarterly earnings and financial guidance
• New product approvals and clinical trials
• Strategic acquisitions in medical technology
• Regulatory compliance updates
• Leadership changes and corporate governance
Bookmark this page for streamlined access to Baxter’s verified news developments. Check regularly for updates that may impact market positioning and healthcare sector trends.
Baxter (NYSE:BAX) and The University of Texas Medical Branch presented retrospective analyses of 1.3 million IV infusions using Spectrum IQ large volume pumps, showing improvements after smart pump–EMR integration at six UTMB hospitals over three years (presented at ASHP Dec 7–10, 2025).
Key results: DERS hard alerts -50.3%, soft alerts -30.4%, SSRC alerts -38.1%; median programming time fell from 10s to 4s; alert-resolution times fell ~50% (soft) and 55% (SSRC).
Baxter (NYSE:BAX) announced pricing and terms for cash tender offers for its 2.600% senior notes due 2026 and 1.915% senior notes due 2027. Key figures per $1,000 principal: $990.50 for 2026 notes and $976.61 for 2027 notes; an $30 early tender payment applies.
The 2026 notes outstanding total $750.0M; 2027 notes outstanding total $1,450.0M. The company set a $600M Maximum Tender Cap for 2027s, causing pro rata acceptance of ~56%, and intends to accept $614.37M aggregate principal of 2027 notes for early settlement on Dec. 8, 2025. Total Consideration was determined Dec. 4, 2025 at 10:00 a.m. ET.
Baxter (NYSE:BAX) announced early tender results for its cash offers to repurchase its 2.600% senior notes due 2026 and 1.915% senior notes due 2027. As of the Early Tender Date of Dec. 3, 2025, holders validly tendered $420,589,000 of 2026 Notes and $1,088,660,000 of 2027 Notes against outstanding amounts of $750,000,000 and $1,450,000,000, respectively.
Baxter elected early settlement on Dec. 8, 2025. Total consideration will be set at 10:00 a.m. ET on Dec. 4, 2025 and includes an early tender payment of $30 per $1,000 principal. The company capped purchases of 2027 Notes at $600 million, so accepted 2027 tenders will be pro rated and the company does not expect to accept 2027 tenders after the Early Tender Date.
Baxter (NYSE:BAX) increased the maximum repurchase cap for its 1.915% Senior Notes due 2027 from $300 million to $600 million under its previously announced cash tender offer, for an aggregate $1.45 billion outstanding of those notes. The terms for the separate 2.600% Senior Notes due 2026 tender offer remain unchanged. The Offer to Purchase dated Nov. 19, 2025 governs the Tender Offers, including the applicable portion of the Financing Condition as modified by this press release. Citigroup, BofA Securities and J.P. Morgan are dealer managers; D.F. King is tender and information agent. This press release is not an offer to purchase securities.
Baxter (NYSE:BAX) commenced tender offers on Nov. 19, 2025 to purchase its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027.
The company will fund the offers subject to conditions using proceeds from a concurrent offering of new senior unsecured notes, and intends to use remaining proceeds to repay other indebtedness, including a term loan that had a $645 million outstanding balance as of Sept. 30, 2025.
Key dates: Early Tender Date Dec. 3, 2025; Price Determination Date Dec. 4, 2025; Expiration Dec. 18, 2025; anticipated settlement Dec. 22, 2025.
Baxter (NYSE:BAX) announced a quarterly cash dividend of $0.01 per share, payable on Jan. 2, 2026 to holders of record as of Nov. 28, 2025. The company said the indicated annual dividend rate is $0.04 per share. Management confirmed the reduction in the quarterly dividend will begin in January 2026 and is expected to free up more than $300 million in annual cash flow to accelerate deleveraging.
Baxter Foundation (NYSE:BAX) announced a $2.6 million, three-year grant to continue its partnership with Northwestern University School of Education and Social Policy to support the Baxter Center for Science Education (BCSE) in Chicagoland.
The funding sustains educator professional development, classroom lab supplies and student STEM experiences. Since 2009 the Foundation has provided nearly $9 million to the BCSE, which has reached about 260,000 students and trained nearly 4,000 teachers across 400+ schools in Cook and Lake counties.
Baxter (NYSE:BAX) will host a third-quarter 2025 financial results conference call on Thursday, October 30, 2025 at 7:30 a.m. Central Time. Investors can pre-register at the provided registration link to receive call details and join the live webcast on Baxter’s website. The call will be recorded and is copyrighted; recording or rebroadcast without permission is prohibited.
Baxter International (NYSE:BAX) has become the first manufacturer to receive the Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) for IV Solutions, Nutrition Solutions, and Premix Drugs categories. This recognition follows the company's earlier achievements of HIRC Transparency Badges in 2023 and 2024.
The award highlights Baxter's excellence in five key areas: resilient global logistics and supply chain visibility, stronger cybersecurity frameworks, enhanced risk management and demand forecasting, inventory oversight, and operational health improvements. The company's Control Tower system provides real-time visibility into its global distribution network, enabling rapid response to emerging issues.
This recognition validates Baxter's commitment to building a more reliable and transparent healthcare supply chain, particularly crucial in maintaining the availability of critical medical supplies.
FAQ
What is the current stock price of Baxter Intl (BAX)?
What is the market cap of Baxter Intl (BAX)?
